Login to Your Account



Clinic Roundup


Tuesday, October 16, 2012

• NPS Pharmaceuticals Inc., of Bedminster, N.J., reported findings from the Phase III REPLACE study of Natpara (recombinant human parathyroid hormone), showing that Natpara initiated bone remodeling as demonstrated by significant increases in bone turnover markers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription